Meet our amazing speaker Dr. Qun Dang will be present his speaker presentation on “Azvudine, a novel nucleoside as effective treatment for HIV and COVID-19 infections with potential for liver cancer.” at the 14GASTROUCG Conference, from December 17-19, 2024 in Holiday Inn Dubai, Al Barsha, UAE & Virtual

 

 As the 14th World Gastroenterology, IBD & Hepatology Conference approaches, the spotlight is on cutting-edge research shaping the future of medicine. Among the most anticipated presentations is Dr. Qun Dang's poster on “Azvudine, a Novel Nucleoside as Effective Treatment for HIV and COVID-19 Infections with Potential for Liver Cancer.”

This innovative research delves into the multifaceted therapeutic potential of Azvudine, a compound poised to revolutionize treatments for infectious diseases and cancer.

A Game-Changer for HIV and COVID-19

Azvudine, a novel nucleoside analog, has shown remarkable efficacy in combating HIV and COVID-19:

HIV: By targeting viral replication, Azvudine provides a new approach to managing HIV, with the potential to enhance treatment regimens.

COVID-19: Amid ongoing challenges in treating SARS-CoV-2, Azvudine has demonstrated significant antiviral activity, offering hope for improved clinical outcomes.

Potential Beyond Infections: Liver Cancer

In addition to its antiviral applications, early studies suggest that Azvudine may have promising anticancer properties. This opens doors to its use in liver cancer, a disease with limited effective treatment options.

Join the Conversation

Dr. Qun Dang’s presentation will provide a comprehensive overview of Azvudine’s mechanisms, clinical data, and its future as a therapeutic agent. This groundbreaking research underscores the importance of collaboration in addressing global health challenges.

Stay tuned for insights from the conference, happening December 15-17, 2023, at the Holiday Inn Dubai, Al Barsha, UAE, and virtually.

About Dr. Qun Dang:

Max received his BS from Jilin University with honors and earned a CGP Chinese national scholarship; he obtained his Ph.D. in organic chemistry from Purdue University in 1992, joined Gensia (later became Metabasis) as a medicinal chemist and worked until 2009 with his last position as director of medicinal chemistry. Max then joined Merck as a Senior Investigator in the External Basic Research department, and then from 2011 to 2013, he was Director of External Medicinal Chemistry, Asia Lead, based in Shanghai facilitating Merck-CRO operations; 2013-2016, he was a Principle Scientist in the exploratory chemistry department at the Kenilworth site. In 2016 he joined Eli Lilly as Asia Head, BD and External Innovation for diabetes and CV research and worked until March 2018 before joining Qilu Pharmaceutical as VP, Global Head of BD and External Innovation with responsibilities for all BD and external collaborations globally including in-license, out-license and setting strategies for drug discovery and external collaborations. From June 2019 to February 2021Max worked at CSPC as corporate VP, President of CSPC Shanghai Research Institute, CEO of InnovStone Therapeutics, responsible for small molecule new drug discovery efforts. In April 2021, Max joined Genuine Biotech as President and responsible for all aspects of company business including corporate strategy, R&D, financing etc. Max has extensive experiences in business development globally and more than 25-years of experiences as a manager of drug discovery programs spanning from early (Target Selection and Validation, Lead Identification) to late (Lead Optimization and candidate selection) stages; led programs that advanced multiple compounds into human clinic trials (two completed Phase 2b POC studies); experiences in therapeutic areas including diabetes, dyslipidemia, hepatitis B and C, liver cancer, liver fibrosis, anemia, viral and bacterial infections; extensive knowledge of Structure-based Drug Design, Medicinal Chemistry, Drug Delivery, Prodrugs, Liver targeting Strategies, Combinatorial, Heterocyclic and Nucleoside Chemistry; more than five years of managing drug discovery programs executed at various CROs. His research activities have led to 91 publications and 60 patents.

Event Details

Date: December 17-19, 2024

Location: Holiday Inn Dubai, Al Barsha, UAE & Virtual
You can register here: https://gastroenterology.utilitarianconferences.com/registration

For more information and registration, visit the conference website. Let’s come together to pave the way for a healthier tomorrow!